Please Wait.....
Report
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F
Market Report I 2025-04-11 I 182 Pages I TechSci Research
Global Rheumatology therapeutics market was valued at USD 26.11 billion in 2024 and is projected to reach USD 37.05 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.98% during the forecast period.
Rheumatology therapeutics is a specialized area of medical science focused on the diagnosis and treatment of rheumatic diseases, which primarily affect the musculoskeletal system-joints, muscles, bones, and connective tissues. These conditions commonly manifest as joint pain, stiffness, inflammation, and limited mobility. The therapeutic approach aims to alleviate symptoms, manage disease progression, and enhance the quality of life for patients.
The increasing incidence and prevalence of conditions such as rheumatoid arthritis, osteoarthritis, and lupus are fueling demand for rheumatology therapeutics. Key contributing factors include an aging global population and lifestyle-related changes. Biologic therapies-such as TNF inhibitors, interleukin inhibitors, and JAK inhibitors-continue to dominate the market, driven by ongoing R&D introducing more effective treatment options.
Key Market Drivers
Rising Prevalence of Rheumatic Diseases
The growing global burden of rheumatic conditions-including osteoarthritis, rheumatoid arthritis, and gout-can be attributed to several interrelated factors. Aging demographics are a major contributor, with conditions like osteoarthritis increasing proportionally with age. In 2019, approximately 528 million people globally were affected by osteoarthritis, representing a 113% rise since 1990. Nearly 73% of these individuals were over the age of 55.
Obesity is another key risk factor. In 2022, one in eight people globally were classified as obese, with adult obesity rates more than doubling since 1990. Additionally, sedentary lifestyles-prevalent in modern societies-have been linked to a surge in musculoskeletal and joint disorders. As of 2022, nearly one-third of adults worldwide were insufficiently physically active.
Genetic predisposition also plays a significant role. For example, heritability in rheumatoid arthritis is estimated at around 60%, with strong associations to specific genetic markers such as HLA. Environmental factors like air pollution have also been linked to the development and exacerbation of these conditions.
Improvements in diagnostic tools and heightened awareness among healthcare professionals have led to earlier and more accurate diagnoses. In the U.S., 21.2% of adults-approximately 53.2 million people-were diagnosed with arthritis between 2019 and 2021. Many of these diseases are chronic, further increasing prevalence due to long-term disease management.
Gender disparities are also notable; rheumatoid arthritis affects women two to three times more frequently than men. Additionally, rheumatic conditions often coexist with comorbidities such as cardiovascular disease and diabetes, compounding the healthcare burden. Regional differences in diet, healthcare access, and lifestyle also influence prevalence rates. Collectively, these factors underscore the growing need for effective rheumatology therapeutics and continued innovation in treatment approaches.
Key Market Challenges
High Cost of Treatment
One of the primary challenges in the rheumatology therapeutics market is the high cost of treatment, particularly for biologic drugs. Despite insurance coverage, patients frequently incur substantial out-of-pocket expenses, leading to treatment non-adherence and poorer health outcomes.
These high costs can exacerbate disparities in care access, particularly among lower-income populations, resulting in delayed diagnoses and suboptimal treatment. Publicly funded healthcare systems also face budgetary constraints that limit the availability and quality of rheumatologic treatments.
Moreover, the cost burden extends to health insurers and employers, often resulting in increased insurance premiums. Concerns over affordability have prompted discussions among policymakers and advocacy groups regarding drug pricing reforms and greater transparency in healthcare costs.
Rheumatic diseases can significantly impair physical functioning, resulting in decreased work productivity and higher disability rates. The combined effect of disease burden and high treatment costs poses economic challenges for individuals and healthcare systems alike.
Although biosimilars hold promise for reducing treatment costs, broader adoption remains a hurdle due to market hesitancy and limited awareness among healthcare providers and patients.
Key Market Trends
Shift Toward Patient-Centric Care
The market is witnessing a paradigm shift toward patient-centered care, with a strong emphasis on shared decision-making. Healthcare providers are involving patients in the development of personalized treatment plans, taking into account disease severity, lifestyle, comorbidities, and individual preferences.
Education and empowerment are integral components of this approach. By equipping patients with a better understanding of their condition and available treatment options, providers can foster more active patient participation in disease management.
Efforts are also being made to address access and affordability challenges. Healthcare institutions are working to minimize financial barriers and ensure equitable access to necessary treatments.
Patient-centric models promote continuous monitoring of disease activity, encouraging patients to communicate regularly with their healthcare teams. Pain management, as a core concern, is customized based on individual needs.
Key Market Players
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Merck & Co., Inc.
- Amgen Inc.
- Novartis AG
- Janssen Pharmaceuticals, Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Private Limited
- F. Hoffmann-La Roche Ltd
Report Scope:
In this report, the Global Rheumatology Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Rheumatology Therapeutics Market, By Indication:
o Ankylosing Spondylitis
o Gout
o Osteoarthritis
o Psoriatic Arthritis
o Rheumatoid Arthritis
- Rheumatology Therapeutics Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
- Rheumatology Therapeutics Market, By Region:
o North America
United States
Canada
Mexico
o Asia-Pacific
China
India
South Korea
Australia
Japan
o Europe
Germany
France
United Kingdom
Spain
Italy
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Rheumatology Therapeutics Market.
Available Customizations:
Global Rheumatology Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Rheumatology Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis)
5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. Asia Pacific Rheumatology Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Rheumatology Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Distribution Channel
6.3.2. India Rheumatology Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Distribution Channel
6.3.3. Australia Rheumatology Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Distribution Channel
6.3.4. Japan Rheumatology Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Indication
6.3.4.2.2. By Distribution Channel
6.3.5. South Korea Rheumatology Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Indication
6.3.5.2.2. By Distribution Channel
7. Europe Rheumatology Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Rheumatology Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Distribution Channel
7.3.2. Germany Rheumatology Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Distribution Channel
7.3.3. Spain Rheumatology Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Rheumatology Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By Distribution Channel
7.3.5. United Kingdom Rheumatology Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By Distribution Channel
8. North America Rheumatology Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Rheumatology Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Distribution Channel
8.3.2. Mexico Rheumatology Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Distribution Channel
8.3.3. Canada Rheumatology Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Distribution Channel
9. South America Rheumatology Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Rheumatology Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Distribution Channel
9.3.2. Argentina Rheumatology Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Distribution Channel
9.3.3. Colombia Rheumatology Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Distribution Channel
10. Middle East and Africa Rheumatology Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Rheumatology Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Distribution Channel
10.3.2. Saudi Arabia Rheumatology Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Distribution Channel
10.3.3. UAE Rheumatology Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Rheumatology Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. AbbVie Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Bristol-Myers Squibb Company
16.3. Pfizer Inc.
16.4. Merck & Co., Inc.
16.5. Amgen Inc.
16.6. Novartis AG
16.7. Janssen Pharmaceuticals, Inc.
16.8. Sanofi SA
16.9. Johnson & Johnson Private Limited
16.10. Takeda Pharmaceutical Company Limited
16.11. F. Hoffmann-La Roche Ltd
17. Strategic Recommendations
18. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security